$3.07
+0.02 (+0.66%)
Open$3.07
Previous Close$3.05
Day High$3.07
Day Low$3.06
52W High$7.13
52W Low$2.82
Volume—
Avg Volume6.5K
Market Cap31.46M
P/E Ratio—
EPS$-3.27
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+1,283.7% upside
Current
$3.07
$3.07
Target
$42.48
$42.48
$23.35
$42.48 avg
$52.53
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.11M | 1.18M | 4.21M |
| Net Income | -35,590,418 | -17,921,656 | -76,163 |
| Profit Margin | -1,690.3% | -1,605.8% | -1.8% |
| EBITDA | -33,574,057 | -17,845,551 | -73,642 |
| Free Cash Flow | — | — | -41,548 |
| Rev Growth | +78.7% | +78.7% | +17.4% |
| Debt/Equity | 250.28 | 250.28 | 0.83 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $207.18 | +0.96% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.93 | +1.58% | 24.4 | 188.06B |
| GILD | Gilead Sciences Inc | $138.26 | +0.11% | 20.0 | 170.34B |
| VRTX | Vertex Pharmaceuticals Inc | $454.97 | +1.42% | 29.2 | 115.53B |
| REGN | Regeneron Pharmaceuticals | $749.47 | +1.05% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.70 | +6.70% | 139.7 | 43.84B |